Biohaven Ltd. (NYSE:BHVN) Shares Bought by American Century Companies Inc.

American Century Companies Inc. boosted its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 558,761 shares of the company’s stock after purchasing an additional 48,286 shares during the quarter. American Century Companies Inc. owned approximately 0.55% of Biohaven worth $20,870,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Spire Wealth Management acquired a new stake in Biohaven in the 4th quarter valued at $56,000. Amalgamated Bank lifted its holdings in Biohaven by 21.9% during the fourth quarter. Amalgamated Bank now owns 2,929 shares of the company’s stock valued at $109,000 after purchasing an additional 527 shares in the last quarter. US Bancorp DE grew its position in shares of Biohaven by 36.7% in the fourth quarter. US Bancorp DE now owns 2,971 shares of the company’s stock valued at $111,000 after purchasing an additional 798 shares during the period. KBC Group NV increased its stake in shares of Biohaven by 50.1% during the fourth quarter. KBC Group NV now owns 3,377 shares of the company’s stock worth $126,000 after purchasing an additional 1,127 shares in the last quarter. Finally, Capstone Investment Advisors LLC purchased a new position in Biohaven in the 3rd quarter valued at about $250,000. 88.78% of the stock is owned by institutional investors and hedge funds.

Biohaven Price Performance

Shares of BHVN opened at $27.59 on Monday. The firm has a 50-day simple moving average of $35.15 and a two-hundred day simple moving average of $41.40. The stock has a market cap of $2.82 billion, a PE ratio of -2.95 and a beta of 1.27. Biohaven Ltd. has a 1-year low of $26.57 and a 1-year high of $55.72.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). As a group, sell-side analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on BHVN shares. JPMorgan Chase & Co. decreased their target price on Biohaven from $72.00 to $68.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 5th. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price target on shares of Biohaven in a research report on Tuesday, March 4th. Morgan Stanley cut their price objective on shares of Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the stock a “buy” rating in a report on Thursday, March 20th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Fourteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $62.77.

Insider Activity

In other news, Director John W. Childs bought 32,700 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was bought at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the acquisition, the director now directly owns 2,320,571 shares of the company’s stock, valued at $70,707,798.37. The trade was a 1.43 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 16.00% of the company’s stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.